Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUC-1031 plus cisplatin versus gemcitabine plus cisplatin in untreated advanced biliary tract cancer
2019-001025-28Phase 3Unknown
- Sponsor
- NuCana
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pracinostat in biliary adenocarcinoma (2 arms), sponsored by NuCana. Primary endpoints: Overall survival and Objective response rate. Status: unknown.
02
Drugs
pracinostat
03
Conditions
biliary adenocarcinoma
Beyond the preview
Go deeper on 2019-001025-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001025-28.